Protamine in treatment of neuronal injuries
The present invention relates to treatment of neuronal injury. The present invention discloses a novel use of an agent and a novel method for promoting neurite out growth and/or neural regeneration in CNS injuries. A novel mechanism of promoting neurite outgrowth by increasing the interaction of chondroitin sulphate proteoglycan (CSPG) to receptor protein tyrosine phosphatase sigma (RPTPσ) is disclosed.
1. A protamine peptide consisting of an amino acid sequence with at least 80% identity to SEQ ID NO: 3.
2. The protamine peptide of claim 1 , wherein the amino acid sequence has at least 90% identity to SEQ ID NO: 3.
3. The protamine peptide of claim 1 , wherein the amino acid sequence is set forth in SEQ ID NO: 3.
4. A method of promoting neurite outgrowth and/or neuronal regeneration, comprising administering an effective amount of the protamine peptide of claim 1 to a patient in need thereof.
5. The method of claim 4 , wherein the subject has experienced a neuronal injury selected from the group consisting of neurodegenerative diseases, traumatic brain injury, spinal cord injury, multiple sclerosis (MS), amyotropic lateral sclerosis (ALS), Parkinson's disease, stroke, peripheral nerve injury, eye injury and skin burn.
6. The method of claim 4 , wherein the administration is one or more selected from the group consisting of intracranial, intracerebrospinal, intravenous and topical.
7. The method of claim 4 , wherein the administration is one or more selected from the group consisting of direct injection and protamine-bound carrier material implantation.
8. A method of promoting neurite outgrowth and/or neuronal regeneration, comprising administering an effective amount of the protamine peptide of claim 1 to a neural cell in vitro.
9. A protamine peptide, consisting of the amino acid sequence set forth in SEQ ID NO: 10.
10. A method of promoting neurite outgrowth and/or neuronal regeneration, comprising administering an effective amount of the protamine peptide of claim 9 to a patient in need thereof.
11. The method of claim 10 , wherein the subject has experienced a neuronal injury selected from the group consisting of neurodegenerative diseases, traumatic brain injury, spinal cord injury, multiple sclerosis (MS), amyotropic lateral sclerosis (ALS), Parkinson's disease, stroke, peripheral nerve injury, eye injury and skin burn.
12. The method of claim 10 , wherein the administration is one or more selected from the group consisting of intracranial, intracerebrospinal, intravenous and topical.
13. The method of claim 10 , wherein the administration is one or more selected from the group consisting of direct injection and protamine-bound carrier material implantation.
14. A method of promoting neurite outgrowth and/or neuronal regeneration, comprising administering an effective amount of the protamine peptide of claim 9 to a neural cell in vitro.